Year in Review: Updates in Treating Myelofibrosis : Episode 4

Opinion

Video

March 13, 2024

Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib

Author(s):

Andrew Kuykendall, MD,Raajit K. Rampal, MD, PhD

Raajit K. Rampal, MD, PhD, discusses promising data on navtemadlin plus ruxolitinib for patients with myelofibrosis who had suboptimal responses to ruxolitinib, showing significant improvements in spleen and symptom responses, with further phase 3 studies anticipated.

EP: 1.How JAK Inhibitors Have Shaped the Landscape of MF

EP: 2.Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2

EP: 3.Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1

EP: 4.Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib

EP: 5.Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034

EP: 6.Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001

EP: 7.Future Directions in Combination Therapies for Myelofibrosis

EP: 8.Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF

EP: 9.The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib

EP: 10.Selection and Sequencing of JAK Inhibitors for Patients With MF

EP: 11.Individualizing Therapy Goals for Patients With Myelofibrosis

EP: 12.Emerging Treatments for Myelofibrosis

Related Videos

Phase 3 AMPLIFY Trial

Guillermo Garcia-Manero, MD

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, highlight key data in CML and ALL presented at the 2024 ASH Annual Meeting.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, detail factors for selecting a TKI in later lines of therapy in chronic myeloid leukemia.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss data for ponatinib plus chemotherapy in Ph-positive ALL.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss dosing strategies for ponatinib in CML and ALL.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the mutational analysis for ponatinib in the OPTIC trial in CP-CML.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss 5-year data for ponatinib in pretreated CP-CML.

Christiane Querfeld, M.D., Ph.D

Naval G. Daver, MD,

Related Content

Hematology | Image credit: © Nittaya – stock.adobe.com

January 29th 2025

Second Primary Cancer Risk Informs the Risk-Benefit Profile of CAR T-Cell Therapies

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital

November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Ashkan Emadi, MD

January 27th 2025

Venetoclax/Pegcrisantaspase Combo Offers Potential to Overcome Venetoclax Resistance in R/R AML

OncLive On Air

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

FDA

January 24th 2025

FDA Approves Treosulfan for alloHCT Conditioning in AML and MDS

Acute Myeloid Leukemia | stock.adobe.com

January 23rd 2025

Maintenance Galinpepimut-S Appears Effective and Safe in AML in Second CR

Related Content

Hematology | Image credit: © Nittaya – stock.adobe.com

January 29th 2025

Second Primary Cancer Risk Informs the Risk-Benefit Profile of CAR T-Cell Therapies

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital

November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Ashkan Emadi, MD

January 27th 2025

Venetoclax/Pegcrisantaspase Combo Offers Potential to Overcome Venetoclax Resistance in R/R AML

OncLive On Air

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

FDA

January 24th 2025

FDA Approves Treosulfan for alloHCT Conditioning in AML and MDS

Acute Myeloid Leukemia | stock.adobe.com

January 23rd 2025

Maintenance Galinpepimut-S Appears Effective and Safe in AML in Second CR

Latest Conference Coverage

T-DM1 Is Not Associated With Improved PFS vs Historical Controls in Pretreated HER2+ Biliary Tract Cancer

OS With Chemotherapy Is Linked With Baseline Geriatric, QOL Factors in Metastatic Pancreatic Cancer

Bezuclastinib Plus Sunitinib Elicits Preliminary Activity, Is Safe in Pretreated GIST

Post-Chemotherapy ctDNA Status May Support Organ Preservation Decisions in Rectal Cancer

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.